- Adalimumab is an anti-TNF drug. In rheumatoid arthritis and some other conditions, too much of a protein called TNF (tumour necrosis factor) is produced in the body, causing inflammation, pain and damage to the bones and joints. Anti-TNF drugs such as adlimumab block the action of TNF and so reduce this inflammation.
- Adalimumab isn’t a painkiller but can modify the disease and improve your symptoms over a period of 2–12 weeks.
- Trade name Of Adalimumab is Humira.
Adalimumab Uses
Adalimumab can be prescribed by a rheumatologist for:
- Rheumatoid arthritis
- Ankylosing spondylitis
- Psoriatic arthritis
- Juvenile idiopathic arthritis (JIA).
It’s often prescribed along with a disease-modifying drug such as methotrexate.
Adalimumab Side Effects
If you have any of these serious side effects of Humira, stop taking it and call your doctor right away:
- Vision problems
- Numbness or tingling
- New joint pain
- Weakness in your legs
- Chest pain
- Shortness of breath
- Swelling of the face, feet, ankles, or lower legs
- Hives
- Itching
- Unusual bruising or bleeding
- Rash on your cheeks or arms that gets worse in the sun
- Trouble breathing or swallowing
- Fever, sore throat, chills, and other signs of infection
- Dizziness
- Pale skin
- Red, scaly patches or raised, pus-filled bumps
- Injection site reactions are common while taking Humira.
Symptoms of these reactions, which typically clear up within a few days, may include:
- Swelling
- Redness
- Bruising
- Itching
Other common side effects of Humira include:
- Nausea
- Headaches
- Upper respiratory infections (including sinus infections)
- Rash
- Back pain
Doses
According To Drugs.com
- Usual Adult Dose for Ankylosing Spondylitis
40 mg subcutaneously every other week - Usual Adult Dose for Rheumatoid Arthritis
40 mg subcutaneously every other week - Usual Adult Dose for Psoriatic Arthritis
40 mg subcutaneously every other week - Usual Adult Dose for Crohn’s Disease – Acute
-Initial dose: 160 mg subcutaneously on Day 1 (given in one day or split over 2 consecutive days), followed by 80 mg subcutaneously 2 weeks later (Day 15)
-Maintenance dose (beginning 2 weeks later [Day 29]): 40 mg subcutaneously every other week - Usual Adult Dose for Crohn’s Disease – Maintenance
-Initial dose: 160 mg subcutaneously on Day 1 (given in one day or split over 2 consecutive days), followed by 80 mg subcutaneously 2 weeks later (Day 15)
-Maintenance dose (beginning 2 weeks later [Day 29]): 40 mg subcutaneously every other week - Usual Adult Dose for Ulcerative Colitis
-Initial dose: 160 mg subcutaneously on Day 1 (given in one day or split over 2 consecutive days), followed by 80 mg subcutaneously 2 weeks later (Day 15)
-Maintenance dose (beginning 2 weeks later [Day 29]): 40 mg subcutaneously every other week - Usual Adult Dose for Uveitis
-Initial dose: 80 mg subcutaneously
-Maintenance dose: 40 mg subcutaneously every other week, starting one week after the initial dose - Usual Adult Dose for Plaque Psoriasis
-Initial dose: 80 mg subcutaneously
-Maintenance dose: 40 mg subcutaneously every other week, starting one week after the initial dose - Usual Adult Dose for Hidradenitis Suppurativa
-Initial dose: 160 mg subcutaneously (given in one day or split over 2 consecutive days), followed by 80 mg subcutaneously 2 weeks later (Day 15)
-Maintenance dose: 40 mg subcutaneously each week beginning on Day 29 - Usual Pediatric Dose for Juvenile Idiopathic Arthritis
2 years and older:
-For 10 kg (22 pounds) to less than 15 kg (33 pounds):10 mg subcutaneously every other week
-For 15 kg (33 pounds) to less than 30 kg (66 pounds): 20 mg subcutaneously every other week
-For 30 kg (66 pounds) or greater: 40 mg subcutaneously every other week - Usual Pediatric Dose for Crohn’s Disease – Acute
6 years and older:
-For 17 kg (37 pounds) to less than 40 kg (88 pounds):
Initial dose: 80 mg subcutaneously (Day 1), then 40 mg subcutaneously 2 weeks later (Day 15)
Maintenance dose: 20 mg subcutaneously every other week
-For 40 kg (88 pounds) or greater:
Initial dose: 160 mg subcutaneously (Day 1) given in one day or split over 2 consecutive days, then 80 mg subcutaneously 2 weeks later (Day 15)
Maintenance dose: 40 mg subcutaneously every other week - Usual Pediatric Dose for Crohn’s Disease – Maintenance
6 years and older:
-For 17 kg (37 pounds) to less than 40 kg (88 pounds):
Initial dose: 80 mg subcutaneously (Day 1), then 40 mg subcutaneously 2 weeks later (Day 15)
Maintenance dose: 20 mg subcutaneously every other week
-For 40 kg (88 pounds) or greater:
Initial dose: 160 mg subcutaneously (Day 1) given in one day or split over 2 consecutive days, then 80 mg subcutaneously 2 weeks later (Day 15)
Maintenance dose: 40 mg subcutaneously every other week.
Learn more information about medicine and supplements here.